Texas Instruments Incorporated (TXN)

Revenue growth above 1.5x ADI's 3.63%. David Dodd would confirm if the firm has a unique advantage driving sales higher.

Gross profit growth above 1.5x ADI's 1.79%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.

EBIT growth above 1.5x ADI's 36.33%. David Dodd would confirm if core operations or niche positioning yield superior profitability.

Operating income growth above 1.5x ADI's 36.33%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.

Net income growth above 1.5x ADI's 26.48%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.

EPS growth above 1.5x ADI's 22.22%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.

Diluted EPS growth above 1.5x ADI's 22.22%. David Dodd would see if there's a robust moat protecting these shareholder gains.

Share reduction while ADI is at 0.05%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.

Reduced diluted shares while ADI is at 0.22%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.

Dividend growth above 1.5x ADI's 0.11%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.

10Y revenue/share CAGR 1.25-1.5x ADI's 53.97%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.

Positive 5Y CAGR while ADI is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.

Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.

10Y OCF/share CAGR above 1.5x ADI's 30.53%. David Dodd would check if a superior product mix or cost edge drives this outperformance.

5Y OCF/share CAGR above 1.5x ADI's 3.05%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.

3Y OCF/share CAGR 1.25-1.5x ADI's 121.76%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.

Net income/share CAGR above 1.5x ADI's 42.12% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.

Positive 5Y CAGR while ADI is negative. John Neff might view this as a strong mid-term relative advantage.

Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.

Positive 5Y equity/share CAGR while ADI is negative. John Neff might see a clear edge in retaining earnings or managing capital better.

Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.

Dividend/share CAGR of 460.05% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.

5Y dividend/share CAGR above 1.5x ADI's 233.91%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.

3Y dividend/share CAGR above 1.5x ADI's 24.39%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.

We show growth while ADI is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.

BV/share growth above 1.5x ADI's 1.52%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.

No Data available this quarter, please select a different quarter.

Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.

We expand SG&A while ADI cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.